Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BactiQuant AS's change in receivables for the quarter that ended in Dec. 2025 was kr-0.27 Mil. It means BactiQuant AS's Accounts Receivable
increased by kr0.27 Mil
from Jun. 2025 to Dec. 2025 .
BactiQuant AS's change in receivables for the fiscal year that ended in Dec. 2025 was kr1.70 Mil. It means BactiQuant AS's Accounts Receivable
declined by kr1.70 Mil
from Dec. 2024 to Dec. 2025 .
Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
BactiQuant AS's Days Sales Outstanding for the
six
months ended in Dec. 2025 was 39.93.
In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. BactiQuant AS's liquidation value for the
six
months ended in Dec. 2025 was kr9.73 Mil.
BactiQuant AS (OCSE:BACTIQ) Change In Receivables Explanation
1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
BactiQuant AS's Days Sales Outstanding for the quarter that ended in Dec. 2025 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BactiQuant AS Change In Receivables Related Terms
BactiQuant AS Change In Receivables Historical Data
* Premium members only.
The historical data trend for BactiQuant AS's Change In Receivables can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.
Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was kr1.70 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Change In Receivables of kr1.70 Mil mean?
BactiQuant AS (OCSE:BACTIQ) has a Change In Receivables of kr1.70 Mil as of Dec. 2025. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for BactiQuant AS and its competitors.
Is BactiQuant AS's Change In Receivables too high?
BactiQuant AS's current Change In Receivables is kr1.70 Mil. Overall, BactiQuant AS has a GF Score™ of 54/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does BactiQuant AS's Change In Receivables compare to VLTO and ZWS?
BactiQuant AS's Change In Receivables of kr1.70 Mil can be compared against companies in the Industrial Products industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for an Industrial Products company?
A good Change In Receivables depends on the Industrial Products industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for BactiQuant AS and its competitors. BactiQuant AS's current Change In Receivables is kr1.70 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BactiQuant AS stock overvalued right now?
Based on GuruFocus' analysis, BactiQuant AS (OCSE:BACTIQ) is currently considered Fairly Valued. The stock's GF Value™ is kr2.30, compared to a current price of kr2.29 — trading 0.4% below its estimated fair value. The current Change In Receivables is kr1.70 Mil. BactiQuant AS's overall GF Score™ is 54/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For BactiQuant AS (OCSE:BACTIQ), the current Change In Receivables is kr1.70 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BactiQuant AS (OCSE:BACTIQ) Overvalued in 2026?
Based on GuruFocus' analysis, BactiQuant AS stock appears to be undervalued.
The current stock price of kr2.29 is trading 0.4% below its estimated GF Value™ of kr2.30.
GuruFocus considers BactiQuant AS to be Fairly Valued.
Key valuation signals for OCSE:BACTIQ:
Change In Receivables: kr1.70 Mil
GF Value™: kr2.30 vs. price of kr2.29 (0.4% below fair value)
No single metric tells the full story. See the OCSE:BACTIQ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BactiQuant AS focuses on delivering technology that ensures optimum usage and handling of water around the world. The company's activities include the development, production, sale and service of BactiQuant Online and BactiQuant Mobile Lab with associated test kits/substrate for the quantification and detection of bacteria in water. Its segments are Aquaculture, Data Centres, Oil & Gas, Water Utility, Industry, and Pharma. The group's products are BQ Online 2.0 PRO, BQ Online, BQ Mobile Lab, and Analysis Kits.
54GF Score
Get the complete analysis for OCSE:BACTIQ
Change In Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OCSE:BACTIQ has been successfully added to your 
